Le Rivaroxaban (Xarelto®): état des lieux des nouvelles données et perspectives thérapeutiques | Louvain Médical
Efficacy Profile - Chronic CAD/PAD | XARELTO® (rivaroxaban) HCP
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System | SpringerLink
Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist
Stroke Outcomes in the COMPASS Trial | Circulation
COMPASS study of Janssen's rivaroxaban to end early for efficacy - 526 Fulham Rd, Fulham, London SW6, UK
COMPASS - Research Studies - PHRI - Population Health Research Institute of Canada
Study design of COMPASS. To assess the safety and efficacy of... | Download Scientific Diagram
Figure 2, COMPASS Design Schematic - Clinical Review Report: Rivaroxaban ( Xarelto) - NCBI Bookshelf
عبدالله خربوش on X: "COMPASS trial: Rivaroxaban with or without aspirin in stable CVD. The NEJM. 2017. epub 2017-08-27:1-12. Further evidence of increased major bleeding with this approach will necessitate careful consideration
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC
COMPASS : Rivaroxaban + aspirine chez le vasculaire
Xarelto® (Rivaroxaban) - COMPASS-studien - Xarelto i kombination med ASA vid kranskärlsjukdom
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin - ScienceDirect
COMPASS: Clinical Trial - Post Revascularization & Chronic PAD | XARELTO® ( rivaroxaban) HCP
COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease | tctmd.com
COMPASS | Xarelto Global
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease | Heart
Studio COMPASS: efficacia dell'associazione rivaroxaban ed aspirina nei pazienti con vasculopatia aterosclerotica stabile - ATBV
COMPASS: Clinical Trial - Post Revascularization & Chronic PAD | XARELTO® ( rivaroxaban) HCP
C. Michael Gibson MD on X: "Here is the design of the COMPASS trial of > 27,000 patients that was shut down due to overwhelming superiority of rivaroxaban https://t.co/abziReBQNk" / X
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial - ScienceDirect
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD | SpringerLink
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial | Journal of the American College of Cardiology
